Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.92
+9.7%
$7.72
$1.95
$12.43
$7.56B0.0213.07 million shs19.04 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$36.00
-0.6%
$38.00
$3.26
$47.84
$2.27B2.32595,372 shs493,424 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$302.68
+1.1%
$274.21
$123.03
$319.48
$8.83B0.5299,641 shs181,924 shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$104.95
+2.8%
$102.40
$70.25
$113.01
$8.07B1.15465,877 shs425,579 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+9.70%+2.06%+6.45%-16.98%+213.04%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-0.63%+4.59%-19.71%+30.34%+946.51%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+1.08%+3.20%+11.07%+11.08%+142.05%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
+2.77%+3.91%+0.43%+0.40%+42.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.92
+9.7%
$7.72
$1.95
$12.43
$7.56B0.0213.07 million shs19.04 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$36.00
-0.6%
$38.00
$3.26
$47.84
$2.27B2.32595,372 shs493,424 shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$302.68
+1.1%
$274.21
$123.03
$319.48
$8.83B0.5299,641 shs181,924 shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$104.95
+2.8%
$102.40
$70.25
$113.01
$8.07B1.15465,877 shs425,579 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+9.70%+2.06%+6.45%-16.98%+213.04%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-0.63%+4.59%-19.71%+30.34%+946.51%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+1.08%+3.20%+11.07%+11.08%+142.05%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
+2.77%+3.91%+0.43%+0.40%+42.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$14.2079.29% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.63
Moderate Buy$42.1417.06% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.83
Moderate Buy$324.117.08% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
2.94
Moderate Buy$140.2933.68% Upside

Current Analyst Ratings Breakdown

Latest KOD, KRYS, NUVL, and IBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Initiated CoverageOutperform$189.00
5/21/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Initiated CoverageOutperform$189.00
5/21/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Reiterated RatingBuy$12.00
5/21/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
UpgradeStrong-Buy
5/20/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Reiterated RatingBuy$15.00
5/18/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Reiterated RatingBuy$310.00
5/11/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
UpgradeNeutralBuy$14.00 ➝ $61.00
5/8/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Set Price Target$12.00
5/5/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Reiterated RatingOutperform$300.00
5/5/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Boost Price TargetBuy$371.00 ➝ $378.00
5/5/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Reiterated RatingBuy$23.00
(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M73.22N/AN/A($0.83) per share-9.54
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$1.79 per shareN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$417.30M21.38$7.37 per share41.08$43.31 per share6.99
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$14.87 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.4840.4728.77N/A53.92%19.25%17.62%8/3/2026 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)

Latest KOD, KRYS, NUVL, and IBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million
5/7/2026Q4 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.93-$0.94-$0.01-$0.94N/AN/A
5/7/2026Q1 2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A
5/4/2026Q1 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.45$1.83+$0.38$1.83$112.11 million$116.36 million
3/31/2026Q4 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.02-$1.04-$0.02-$1.04N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
6.67
6.66
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
3.54
3.54
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.46
9.06
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
16.14
16.14

Institutional Ownership

CompanyInstitutional Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%

Insider Ownership

CompanyInsider Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
69.48%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
45.90%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5901.05 billion319.65 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9062.58 million33.86 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21029.48 million25.62 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4079.00 million75.03 millionOptionable

Recent News About These Companies

Guggenheim Sticks to Their Buy Rating for Nuvalent (NUVL)
Canaccord Genuity Remains a Buy on Nuvalent (NUVL)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$7.92 +0.70 (+9.70%)
As of 05/26/2026 04:00 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$36.00 -0.23 (-0.63%)
As of 05/26/2026 04:00 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$302.68 +3.23 (+1.08%)
As of 05/26/2026 04:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$104.95 +2.83 (+2.77%)
As of 05/26/2026 04:00 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.